Mimedx achieved record net sales of $114 million in Q3 2025, a 35% increase year-over-year, with significant growth in both its Wound and Surgical product categories. The company also reported strong GAAP net income of $17 million and adjusted EBITDA of $35 million, representing a 31% margin, and raised its full-year 2025 net sales growth and adjusted EBITDA expectations.
Mimedx reported record net sales of $114 million for Q3 2025, marking a 35% increase compared to the prior year.
Both Wound and Surgical product categories demonstrated strong growth, with Wound sales increasing by 40% and Surgical sales by 26% year-over-year.
GAAP net income for the quarter was $17 million, and diluted EPS was $0.11, significantly up from $8 million and $0.05 respectively in Q3 2024.
Adjusted EBITDA reached $35 million, or 31% of net sales, reflecting improved operational efficiencies and profitability.
Mimedx has raised its full-year 2025 net sales growth expectations to the mid-to-high teens and anticipates an Adjusted EBITDA margin of at least the mid-20% range. The company maintains a long-term outlook of low double-digit annual net sales growth and an Adjusted EBITDA margin above 20%.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance